CYTK.NASDAQCytokinetics INC

Form 4: Cytokinetics CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Robert I Blum, President & CEO and a Director of Cytokinetics Inc, sold 7,500 shares of common stock on September 28, 2026 for $65.46 per share.

Summary

  • Option exercise/conversion: acquired 7,500 Common Stock at $10.60 ($79,500) on September 28, 2026; holds 286,044 after (Direct).
  • Open-market sale: disposed of 7,500 Common Stock at $65.46 ($490,950) on September 28, 2026; holds 278,544 after (Direct).
  • Option exercise/conversion: disposed of 7,500 Non-Qualified Stock Option (Right to Buy) on September 28, 2026; holds 149,245 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $490,950 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Robert I Blum — Director, Officer (President & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-09-28Option exercise/conversionCommon Stock7,500$11$79.5K286,044
2026-09-28Open-market saleCommon Stock7,500$65$490.9K278,544
2026-09-28Option exercise/conversionNon-Qualified Stock Option (Right to Buy)7,500——149,245

Key Dates

DateDescription
2026-09-28Option exercise/conversion (7,500 shares)
2026-09-28Open-market sale (7,500 shares)
2026-09-28Option exercise/conversion (7,500 shares)

Keywords

insider transaction, Form 4, CYTK, CYTOKINETICS INC, bearish, Robert I Blum

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.